These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 18338781)

  • 1. Increased incidence of urinary matrix metalloproteinases as predictors of disease in pediatric patients with inflammatory bowel disease.
    Manfredi MA; Zurakowski D; Rufo PA; Walker TR; Fox VL; Moses MA
    Inflamm Bowel Dis; 2008 Aug; 14(8):1091-6. PubMed ID: 18338781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of matrix metalloproteinases and their tissue inhibitors in inflammatory bowel diseases.
    Lakatos G; Hritz I; Varga MZ; Juhász M; Miheller P; Cierny G; Tulassay Z; Herszényi L
    Dig Dis; 2012; 30(3):289-95. PubMed ID: 22722554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous Assessment of Urinary and Fecal Volatile Organic Compound Analysis in De Novo Pediatric IBD.
    El Manouni El Hassani S; Bosch S; Lemmen JPM; Brizzio Brentar M; Ayada I; Wicaksono AN; Covington JA; Benninga MA; de Boer NKH; de Meij TGJ
    Sensors (Basel); 2019 Oct; 19(20):. PubMed ID: 31623289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary leukotriene E4 excretion: a biomarker of inflammatory bowel disease activity.
    Stanke-Labesque F; Pofelski J; Moreau-Gaudry A; Bessard G; Bonaz B
    Inflamm Bowel Dis; 2008 Jun; 14(6):769-74. PubMed ID: 18286646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary metabolic insights into host-gut microbial interactions in healthy and IBD children.
    Martin FP; Su MM; Xie GX; Guiraud SP; Kussmann M; Godin JP; Jia W; Nydegger A
    World J Gastroenterol; 2017 May; 23(20):3643-3654. PubMed ID: 28611517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary Metabolic Phenotyping Reveals Differences in the Metabolic Status of Healthy and Inflammatory Bowel Disease (IBD) Children in Relation to Growth and Disease Activity.
    Martin FP; Ezri J; Cominetti O; Da Silva L; Kussmann M; Godin JP; Nydegger A
    Int J Mol Sci; 2016 Aug; 17(8):. PubMed ID: 27529220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum MMPs 7-9 and their inhibitors during glucocorticoid and anti-TNF-α therapy in pediatric inflammatory bowel disease.
    Mäkitalo L; Rintamäki H; Tervahartiala T; Sorsa T; Kolho KL
    Scand J Gastroenterol; 2012 Jul; 47(7):785-94. PubMed ID: 22519363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary biomarkers predict brain tumor presence and response to therapy.
    Smith ER; Zurakowski D; Saad A; Scott RM; Moses MA
    Clin Cancer Res; 2008 Apr; 14(8):2378-86. PubMed ID: 18413828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced expression of MMP-7 and MMP-13 in inflammatory bowel disease: a precancerous potential?
    Rath T; Roderfeld M; Graf J; Wagner S; Vehr AK; Dietrich C; Geier A; Roeb E
    Inflamm Bowel Dis; 2006 Nov; 12(11):1025-35. PubMed ID: 17075343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix metalloproteinases (MMP-3 and MMP-9) implication in the pathogenesis of inflammatory bowel disease (IBD).
    Siloşi I; Boldeanu MV; Mogoantă SŞ; Ghiluşi M; Cojocaru M; Biciuşcă V; Cojocaru IM; Avrămescu CS; Gheonea DI; Siloşi CA; Turculeanu A
    Rom J Morphol Embryol; 2014; 55(4):1317-24. PubMed ID: 25611261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of inflammatory bowel disease with urinary metabolic profiling.
    Williams HR; Cox IJ; Walker DG; North BV; Patel VM; Marshall SE; Jewell DP; Ghosh S; Thomas HJ; Teare JP; Jakobovits S; Zeki S; Welsh KI; Taylor-Robinson SD; Orchard TR
    Am J Gastroenterol; 2009 Jun; 104(6):1435-44. PubMed ID: 19491857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary excretion of N-methylhistamine as a marker of disease activity in inflammatory bowel disease.
    Winterkamp S; Weidenhiller M; Otte P; Stolper J; Schwab D; Hahn EG; Raithel M
    Am J Gastroenterol; 2002 Dec; 97(12):3071-7. PubMed ID: 12492192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix metalloproteinases in the urine and tissue of patients with juvenile polyps: potential biomarkers for the presence of polyps.
    Manfredi MA; Fox VL; Zurakowski D; Kutok JL; Glickman JN; Moses MA
    J Pediatr Gastroenterol Nutr; 2009 Apr; 48(4):405-11. PubMed ID: 19330927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species.
    Roy R; Louis G; Loughlin KR; Wiederschain D; Kilroy SM; Lamb CC; Zurakowski D; Moses MA
    Clin Cancer Res; 2008 Oct; 14(20):6610-7. PubMed ID: 18927302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn's disease phenotype.
    Meijer MJ; Mieremet-Ooms MA; van der Zon AM; van Duijn W; van Hogezand RA; Sier CF; Hommes DW; Lamers CB; Verspaget HW
    Dig Liver Dis; 2007 Aug; 39(8):733-9. PubMed ID: 17602907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered levels of biochemical indices of bone turnover and bone-related vitamins in patients with Crohn's disease and ulcerative colitis.
    Gilman J; Shanahan F; Cashman KD
    Aliment Pharmacol Ther; 2006 Apr; 23(7):1007-16. PubMed ID: 16573803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fragments of Citrullinated and MMP-degraded Vimentin and MMP-degraded Type III Collagen Are Novel Serological Biomarkers to Differentiate Crohn's Disease from Ulcerative Colitis.
    Mortensen JH; Godskesen LE; Jensen MD; Van Haaften WT; Klinge LG; Olinga P; Dijkstra G; Kjeldsen J; Karsdal MA; Bay-Jensen AC; Krag A
    J Crohns Colitis; 2015 Oct; 9(10):863-72. PubMed ID: 26188349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selected Cytokines and Metalloproteinases in Inflammatory Bowel Disease.
    Sosna B; Aebisher D; Myśliwiec A; Dynarowicz K; Bartusik-Aebisher D; Oleś P; Cieślar G; Kawczyk-Krupka A
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased expression of CXCR3 axis components and matrix metalloproteinase in pediatric inflammatory bowel disease patients.
    Jimbo K; Ohtsuka Y; Kojima Y; Hosoi K; Ohbayashi N; Ikuse T; Aoyagi Y; Fujii T; Kudo T; Shimizu T
    Pediatr Int; 2014 Dec; 56(6):873-883. PubMed ID: 24750209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the anti-tumor necrosis factor-alpha antibody infliximab on the ex vivo mucosal matrix metalloproteinase-proteolytic phenotype in inflammatory bowel disease.
    Meijer MJ; Mieremet-Ooms MA; van Duijn W; van der Zon AM; Hanemaaijer R; Verheijen JH; van Hogezand RA; Lamers CB; Verspaget HW
    Inflamm Bowel Dis; 2007 Feb; 13(2):200-10. PubMed ID: 17206679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.